Malaria kills ∼600,000 people annually despite recently deployed vaccines. The parasite’s blood-stage invasion of erythrocytes, driven by the essential, non-redundant interaction between Plasmodium falciparum RH5 and erythrocyte basigin, remains a leading therapeutic target. Here, we designed de novo mini-proteins (“mi...
Jason Hsiao, Melina Shamshoum, Abhiram Chalamalasetty et al.· bioRxiv· 0 citations
Despite considerable progress in prevention, treatment, and eradication efforts, malaria continues to impose a significant public health and socioeconomic burden for many countries around the globe. With the effectiveness of current treatment options partially or totally compromised due to resistance, the validation of...
Pedro Martín-Acosta, Abbas H. K. Al Temimi, Luma Godoy Magalhaes et al.· ACS Omega· 0 citations
The rapid emergence of resistance in the malaria-causing protozoan Plasmodium falciparum has heightened the demand for treatments with novel modes of action. Having evolved to produce a myriad of structurally diverse natural products (NPs) as defenses against soil-dwelling parasites including protozoa, Actinomycetota s...
Chantal D. Bader, Jennifer E. Collins, Yue-Lan Li et al.· Journal of the American Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
